We found the prognostic value of WT1 requires the presence of tumor-infiltrating CD3+ T cells: the WT1 antigen appeared with a strong stimulatory effect (for nearly 70% of patients, 9-10 months of improved PFS when co-expressing high levels of CD3). Here, WT1 is linked to neoplasm.